<DOC>
	<DOC>NCT01196897</DOC>
	<brief_summary>This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater. This is a prospective, non-randomized study to evaluate the initial use of the next generation WATCHMAN Device.</brief_summary>
	<brief_title>Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Key Paroxysmal, persistent, or permanent nonvalvular atrial fibrillation Eligible for longterm Warfarin therapy; Eligible to come off Warfarin therapy if the LAA is sealed Calculated CHADS2 score of 1 or greater Key New York Heart Association Class IV Congestive Heart Failure Recent MI (within 3 months) ASD and/or atrial septal repair or closure device Resting heart rate &gt;110 bpm Has an implanted mechanical valve prosthesis Left atrial appendage is obliterated Has undergone heart transplantation Has symptomatic carotid disease Contraindicated for aspirin LVEF &lt; 30% Cardiac Tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Coumadin</keyword>
	<keyword>TIA</keyword>
	<keyword>Trans Ischemic Attack</keyword>
</DOC>